

January 02, 2026

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

**Trading Symbol: ZOTA**

**Sub: Intimation of Wholly Owned Subsidiary of the Company to be incorporated in the name of “KMHP VENTURES LIMITED”**

**Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the “Company”) in its Meeting held on Friday, January 02, 2026 approved for incorporating a Wholly Owned Subsidiary Company with the name and style of ‘KMHP Ventures Limited’ having an total paid up capital of Rs. 10,00,000/-, the Company shall subscribe to 100% of paid up share capital i.e. 1,00,000 equity shares of Rs. 10/- each of the KMHP VENTURES LIMITED, by making an investment of Rs. 10,00,000/-.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is annexed herewith as **Annexure-I**.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**

**Place:** Surat

**Encl:** a/a

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)  
CIN: L24231GJ2000PLC038352

**Annexure – I**

<b>Particulars</b>	<b>Details</b>
<b>Name of the target entity, details in brief such as size, turnover etc.</b>	Name: KMHP VENTURES LIMITED as approved by the Ministry of Corporate Affairs. Authorized Capital: ₹10,00,000/- Turnover: Not Applicable since the Company is yet to be incorporated.
<b>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”</b>	The wholly owned subsidiary company once incorporated will be related party of the Company.
<b>Industry to which the entity being acquired belongs</b>	Pharmaceutical
<b>Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</b>	The proposed company will be engaged in the business of marketing and trading of pharmaceutical products.
<b>Brief details of any governmental or regulatory approvals required for the acquisition</b>	N.A.
<b>Indicative time period for completion of the acquisition</b>	N.A.
<b>Nature of consideration - whether cash consideration or share swap and details of the same;</b>	Cash consideration by way of acquisition of Equity Shares
<b>Cost of acquisition or the price at which the shares are acquired</b>	N.A.
<b>Percentage of shareholding / control acquired and / or number of shares acquired</b>	100%
<b>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)</b>	Not applicable since the Company is yet to be incorporated.